Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24086403 | 0.93 | MAPT (0.50) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24496995 | 0.92 | MAPT (0.46) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL22746546 | 0.91 | MAPT (0.50) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24500277 | 0.91 | MAPT (0.46) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24064765 | 0.89 | MAPT (0.48) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24715149 | 0.89 | MAPT (0.44) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL24500276 | 0.88 | MAPT (0.47) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL16643859 | 0.88 | MAPT (0.45) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL23554179 | 0.87 | TP53 (0.46) | MAPTTP53GAAPOLBLMNA | |
| SCHEMBL19726841 | 0.86 | MAPT (0.43) | MAPTTP53GAAPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175951-A1 | Anti-CD45 Antibody Drug Conjugates and Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20210379195-A1 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | REGENERON PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | MAPT 4561/4885TP53 339/4885GAA 779/4885 |
| US-20210379195-A1 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | CD81, CD2, CD44 | MAPT 4611/4885TP53 609/4885GAA 878/4885 |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | MAPT 4451/4885TP53 334/4885GAA 1194/4885 |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | CD44, LY6K, CD2 | MAPT 2706/4885TP53 1456/4885GAA 351/4885 |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ITGB7, KIT, CD2 | MAPT 3616/4885TP53 2390/4885GAA 494/4885 |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | SIGLEC7, FUT7, ITGB7 | MAPT 3320/4885TP53 1583/4885GAA 317/4885 |
| US-20220175951-A1 | Anti-CD45 Antibody Drug Conjugates and Uses Thereof | CD47, ICOS, CD44 | MAPT 3177/4885TP53 1467/4885GAA 866/4885 |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | CD2, CD4, CD22 | MAPT 2378/4885TP53 690/4885GAA 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.